All In Biotech

NDA 020965 · Sun Pharm Inds INC

Levulan

Aminolevulinic Acid Hydrochloride · Topical

Novel

Last checked: Nov 20, 2026Latest source record: May 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Dec 3, 1999

Approved uses

3

Original approval plus efficacy supplements

Registered trials

200

40 Phase 3, 19 recruiting

FAERS reports

1,433

182 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 12, 2024.

The LEVULAN KERASTICK for topical solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face, scalp, or upper extremities. LEVULAN KERASTICK for topical solution, a porphyrin precursor, plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for photodynamic therapy (treatment) of minimally to moderately thick actinic keratoses of the face or scalp, or actinic keratoses of the upper extremities. ( 1 )

Mechanism: Following the application of LEVULAN KERASTICK topical solution, photosensitization occurs through the metabolic conversion of aminolevulinic acid to protoporphyrin IX (PpIX), a photosensitizer, which accumulates in the skin. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoreactive porphyrins to molecular oxygen...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LEVULAN · AMINOLEVULINIC ACID HYDROCHLORIDE 20% · SOLUTION, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aminolevulinic Acid" as an intervention, any sponsor and status, largest first.

All 200 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective244
  • wrong technique in product usage process182
  • poor quality product administered177
  • product quality issue153
  • product dose omission issue114
  • erythema102
  • accidental exposure to product79
  • off label use78
  • pain63
  • product physical issue62
  • blister48
  • application site pain42

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20123
20136
20146
201513
201677
201764
201887
201977
2020172
202166
2022115
2023167
2024212
2025235
2026133

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Levulan (Aminolevulinic Acid HCl)

2024 spending

$211K

Beneficiaries

359

439 claims

Per beneficiary

$586

$384.83 per unit

View as table
YearSpending
2020$140,395
2021$161,219
2022$196,105
2023$309,611
2024$210,503

Part B: Levulan (Aminolevulinic Acid HCL) · HCPCS J7308

2024 spending

$42.0M

Beneficiaries

65,877

96,953 claims

Per beneficiary

$637

2024 ASP limit $395.27 per unit

View as table
YearSpending
2020$36,413,945
2021$36,088,117
2022$37,902,550
2023$39,915,627
2024$41,988,895

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 553 on PubMed

Sponsor: Sun Pharm Inds INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.